default author photo

Karen H. Lu

University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine

1515 Holocombe Blvd

Houston, TX 77030

United States

SCHOLARLY PAPERS

3

DOWNLOADS

121

TOTAL CITATIONS

0

Scholarly Papers (3)

1.

Interval Salpingectomy and Delayed Oophorectomy Versus Risk-Reducing Salpingo-Oophorectomy in Women at Risk for Hereditary Ovarian Carcinoma: A Prospective Multi-Site Trial

Number of pages: 31 Posted: 11 Nov 2020
University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Washington - Department of Obstetrics and Gynecology, Memorial Sloan Kettering Cancer Center - Department of Surgery, Mayo Clinic - Department of Obstetrics and Gynecology, University of Chicago - Department of Obstetrics and Gyneoclogy, Harvard University - Brigham and Women's Hospital, Department of Obstetrics and Gynecology, New York University (NYU) - Laura and Isaac Perlmutter Cancer Center, Division of Gynecologic Oncology, University of Pennsylvania - Department of Obstetrics and Gynecology, Washington University in St. Louis - Department of Obstetrics and Gynecology, Memorial Sloan Kettering Cancer Center - Department of Surgery, University of Washington - Department of Obstetrics and Gynecology, University of Melbourne - Department of Obstetrics and Gynaecology, Independent, Minnesota Ovarian Cancer Alliance, FORCE: Facing Hereditary Cancer Empowered, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, Dana-Farber Cancer Institute - Center for DNA Damage and Repair and University of Washington - Department of Obstetrics and Gynecology
Downloads 53 (1,031,043)

Abstract:

Loading...

BRCA1, BRCA2, ovarian cancer, prevention

2.

Phase II Trial of Pembrolizumab in Combination with Chemotherapy for Frontline Treatment of Advanced Epithelial Ovarian Cancer

Number of pages: 44 Posted: 28 Mar 2024
University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Genomic Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Translational Molecular Pathology, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, Texas Oncology, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, Texas Oncology, University of Texas at Houston - Department of Genomic Medicine and University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine
Downloads 49 (1,074,648)

Abstract:

Loading...

pembrolizumab, combination chemotherapy, ovarian cancer, immunotherapy, tumor immune microenvironment, translational, clinical trial, feasibility

3.

Phase 1b Study of Batiraxcept (AVB-S6-500) in Combination with Durvalumab (MEDI4736) in Patients with Platinum-Resistant Ovarian Cancer

Number of pages: 27 Posted: 01 Feb 2024
University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, Aravive Biologics, Inc., Aravive Biologics, Inc., University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - MD Anderson Cancer Center, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine, University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine and University of Texas at Houston - Department of Gynecologic Oncology and Reproductive Medicine
Downloads 19 (1,459,862)

Abstract:

Loading...

immune checkpoint inhibitor, AXL inhibitor, Batiraxcept, platinum-resistant ovarian cancer